<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC1884190/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Lack of effect of ketoconazole on the pharmacokinetics of
rosuvastatin in healthy subjects</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC1884190/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects" />
<meta name="citation_authors" content=
"Kelvin J Cooper, Paul D Martin, Aaron L Dane, Mike J Warwick, Ali Raza, Dennis W Schneck" />
<meta name="citation_date" content="January 2003" />
<meta name="citation_issue" content="1" />
<meta name="citation_volume" content="55" />
<meta name="citation_firstpage" content="94" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.2003.01720.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC1884190/?report=abstract" />
<meta name="citation_pmid" content="12534645" />
<meta name="DC.Title" content=
"Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="Kelvin J Cooper" />
<meta name="DC.Contributor" content="Paul D Martin" />
<meta name="DC.Contributor" content="Aaron L Dane" />
<meta name="DC.Contributor" content="Mike J Warwick" />
<meta name="DC.Contributor" content="Ali Raza" />
<meta name="DC.Contributor" content="Dennis W Schneck" />
<meta name="DC.Date" content="2003 Jan" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.2003.01720.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To examine in vivo the effect of ketoconazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.This was a randomized, double-blind, two-way crossover, placebo-controlled trial. Healthy male ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884190/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC1884190/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC1884190/pdf/bcp0055-0094.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FC2AE5763005310000000000A223F6" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/144659/">v.55(1); 2003 Jan</a></li>
<li class="accid">PMC1884190</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2003 Jan; 55(1):
94–99.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.2003.01720.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.2003.01720.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC1884190</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Lack of effect of ketoconazole on the
pharmacokinetics of rosuvastatin in healthy subjects</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Cooper%20KJ%5Bauth%5D">Kelvin J Cooper</a>, <a href=
"/pubmed/?term=Martin%20PD%5Bauth%5D">Paul D Martin</a>, <a href=
"/pubmed/?term=Dane%20AL%5Bauth%5D">Aaron L Dane</a>, <a href=
"/pubmed/?term=Warwick%20MJ%5Bauth%5D">Mike J Warwick</a>, <a href=
"/pubmed/?term=Raza%20A%5Bauth%5D">Ali Raza</a>,<sup>1</sup> and
<a href="/pubmed/?term=Schneck%20DW%5Bauth%5D">Dennis W
Schneck</a><sup>2</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id251923_ai" style="display:none">
<div class="fm-affl" lang="en">AstraZeneca, Alderley Park,
Macclesfield, UK</div>
<div class="fm-affl" lang="en"><sup>1</sup>AstraZeneca, Wayne,
Philadelphia, USA</div>
<div class="fm-affl" lang="en"><sup>2</sup>AstraZeneca, Wilmington,
Delaware, USA</div>
<div id="cor1">Correspondence: Paul D. Martin, AstraZeneca,
Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. Tel.:
+ 44 0 1625 518171; Fax: + 44 0 1625 516962; E-mail: <a href=
"mailto:dev@null" data-email="moc.acenezartsa@nitram.luap" class=
"oemail">moc.acenezartsa@nitram.luap</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id251923_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id251923_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id251923_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id251923_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 2002 Mar 25; Accepted
2002 Jun 13.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id251923_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2003 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC1884190/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid861066" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid861066title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To examine <em>in vivo</em> the
effect of ketoconazole on the pharmacokinetics of rosuvastatin, a
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">This was a randomized,
double-blind, two-way crossover, placebo-controlled trial. Healthy
male volunteers (<em>n</em> = 14) received ketoconazole 200 mg or
placebo twice daily for 7 days, and rosuvastatin 80 mg was
coadministered on day 4 of dosing. Plasma concentrations of
rosuvastatin, and active and total HMG-CoA reductase inhibitors
were measured up to 96 h postdose.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">Following coadministration with
ketoconazole, rosuvastatin geometric least square mean
AUC(0,<em>t</em>) and <em>C</em><sub>max</sub> were unchanged
compared with placebo (treatment ratios (90% confidence intervals):
1.016 (0.839, 1.230), 0.954 (0.722, 1.260), respectively).
Rosuvastatin accounted for essentially all of the circulating
active HMG-CoA reductase inhibitors and most (&gt; 85%) of the
total inhibitors. Ketoconazole did not affect the proportion of
circulating active or total inhibitors accounted for by circulating
rosuvastatin.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">Ketoconazole did not produce
any change in rosuvastatin pharmacokinetics in healthy subjects.
The data suggest that neither cytochrome P450 3A4 nor P-gp-mediated
transport contributes to the elimination of rosuvastatin.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">CYP3A4, ketoconazole, P-glycoprotein,
rosuvastatin</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">Rosuvastatin (Crestor®) is an
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, the rate-limiting enzyme in cholesterol biosynthesis,
and is effective for the treatment of patients with dyslipidaemia.
In clinical trials, rosuvastatin (1-80 mg) produced highly
significant dose-dependent reductions in low-density lipoprotein
cholesterol (up to 65%) and was well-tolerated [<a href="#b1" rid=
"b1" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180316">1</a>].</p>
<p id="__p6">The pharmacokinetics of rosuvastatin following single-
and multiple-dose administration of the drug to healthy volunteers
have been investigated in several trials ([<a href="#b2" rid="b2"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_384404582">2</a>] and AstraZeneca data on file [manuscript
in preparation]). The absolute oral bioavailability was estimated
as 20.1%, which, together with an estimated hepatic extraction
ratio of 0.63, implies that absorption was greater than 20%.
Systemic exposure was dose proportional over the dose range 10–80
mg, and the elimination half-life was about 20 h.</p>
<p id="__p7">Elimination of rosuvastatin is primarily via the
liver. In a clinical trial [<a href="#b3" rid="b3" class=
" bibr popnode">3</a>], 90% of an orally administered dose of
<sup>14</sup>C-radiolabelled rosuvastatin was recovered in faeces
as unchanged drug, a result consistent with metabolism being a
minor route of clearance. <em>In vitro</em> studies with human
hepatic microsomes and hepatocytes demonstrated only limited
metabolism of rosuvastatin [<a href="#b4" rid="b4" class=
" bibr popnode">4</a>], and cytochrome P450 2C9 (CYP2C9) appeared
to be the principal enzyme involved [<a href="#b4" rid="b4" class=
" bibr popnode">4</a>], with minor roles for CYP3A4 and CYP2C19
[<a href="#b4" rid="b4" class=" bibr popnode">4</a>]. In addition,
rosuvastatin had no significant inhibitory effect on the major CYP
isoforms in human hepatic microsomes [<a href="#b4" rid="b4" class=
" bibr popnode">4</a>].</p>
<p id="__p8">Some of the other HMG-CoA reductase inhibitors
(atorvastatin [<a href="#b5" rid="b5" class=" bibr popnode">5</a>],
simvastatin [<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180319">6</a>], and lovastatin [<a href="#b7" rid="b7"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180330">7</a>]) are cleared primarily by metabolism
involving CYP3A4. Thus, there is potential for interactions between
these compounds and coadministered drugs affecting CYP3A4 activity.
It has been shown that the metabolism of atorvastatin [<a href=
"#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180318">8</a>–<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180331">10</a>], simvastatin [<a href="#b11" rid="b11"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180314">11</a>, <a href="#b12" rid="b12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180315">12</a>], and lovastatin [<a href="#b13" rid="b13"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180321">13</a>, <a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180328">14</a>] is inhibited by erythromycin and
itraconazole, leading to increased serum/plasma drug concentrations
and changes in their metabolic profiles.</p>
<p id="__p9">Although <em>in vitro</em> data suggest that CYP3A4
metabolism is not an important clearance mechanism for
rosuvastatin, an <em>in vivo</em> interaction with coadministered
drugs that inhibit CYP3A4 cannot be excluded. Accordingly, the
present study was conducted to assess the effect of ketoconazole (a
potent CYP3A4 inhibitor [<a href="#b15" rid="b15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180324">15</a>]) on the pharmacokinetics of
rosuvastatin.</p>
<p id="__p10" class="p p-last">Ketoconazole is also known to
inhibit the activity of transport protein P-glycoprotein (P-gp)
[<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180327">16</a>]. Active- or facilitated-transport
processes may have a role in the absorption and disposition of
rosuvastatin. Thus, studies with rats have demonstrated selective
hepatic uptake of rosuvastatin by an active transport process
[<a href="#b17" rid="b17" class=" bibr popnode">17</a>], and
rosuvastatin was shown to be a ligand for a liver-specific human
organic-anion-transporting polypeptide present in the basolateral
membranes of hepatic cells [<a href="#b18" rid="b18" class=
" bibr popnode">18</a>], although the identity of these
transporters has not yet been clearly defined. Thus, the results of
the present study may provide an indication of whether
P-gp-mediated transport contributes to rosuvastatin
disposition.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<p id="__p11" class="p p-first">This trial was conducted in
accordance with good clinical practice and the Declaration of
Helsinki. All volunteers gave written informed consent, and a local
independent ethics committee approved the protocol before the trial
started.</p>
<div id="__sec7" class="sec">
<h3>Trial population</h3>
<p id="__p12" class="p p-first">Healthy adult (18–65 years) male
volunteers with no clinically relevant conditions identified from
their medical history, physical examination, or electrocardiogram
(ECG) were included in the trial. Volunteers were excluded if they
had any clinically relevant abnormalities in clinical chemistry,
haematology, or urinalysis results, or if total bilirubin, alanine
aminotransferase, aspartate aminotransferase, alkaline phosphatase,
or creatine kinase were outside the normal reference range at the
start of the trial.</p>
<p id="__p13" class="p p-last">Fourteen male Caucasian volunteers
were enrolled. Their mean (range) age, height, and weight were 24.1
years (21–31), 182.1 cm (170–189), and 73.5 kg (60–83),
respectively. Pharmacokinetic data were available from 13
volunteers [one volunteer withdrew due to personal reasons during
the washout period following the first dosing period (rosuvastatin
+ placebo)]. This withdrawal was considered unlikely to have
affected interpretation of the trial data.</p>
</div>
<div id="__sec8" class="sec">
<h3>Trial design</h3>
<p id="__p14" class="p p-first">This randomized, double-blind,
two-way crossover, placebo-controlled trial (4522IL/0057) was
conducted at a single centre (AstraZeneca R&amp;D, Lund, Sweden).
Volunteers were randomized to receive daily oral doses of
ketoconazole 400 mg (1 × 200-mg tablet every 12 h) or matching
placebo (one tablet every 12 h) for 7 days, with a 2-week washout
period between dosing periods. On day 4 of each dosing period,
volunteers were given a single oral dose of rosuvastatin 80 mg (1 ×
80-mg encapsulated tablet) with the morning dose of ketoconazole or
placebo. Volunteers then remained in the Clinical Pharmacology Unit
for the following 24 h.</p>
<p id="__p15" class="p p-last">During the trial there were
restrictions relating to the consumption of alcohol and physical
exercise (none permitted from 96 h before the first dose on day 1
until 96 h after administration of rosuvastatin in each dosing
period), the consumption of caffeine-containing drinks/food and
smoking (none permitted from midnight before day 1 until 96 h after
administration of rosuvastatin in each dosing period), and
concomitant medications (none permitted from 96 h before the first
dose on day 1 until after the post-trial medical).</p>
</div>
<div id="__sec9" class="sec">
<h3>Determination of rosuvastatin plasma concentrations</h3>
<p id="__p16" class="p p-first">Blood samples (9 ml) for
rosuvastatin assay were taken before administration of rosuvastatin
on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8, 10,
12, 18, 24, 30, 48, 54, 72, and 96 h postdose. Additional samples
were taken before administration of the first dose of ketoconazole
or placebo on day 1 of the second dosing period. Blood samples were
collected into tubes containing lithium heparin anticoagulant and
centrifuged within 30 min. Plasma was then harvested from the
samples, mixed 1:1 with sodium acetate buffer 0.1 <span class=
"small-caps">m</span> pH 4.0, and stored at −70°C until assay.</p>
<p id="__p17" class="p p-last">Plasma samples were analysed using a
validated method (high-performance liquid chromatography with
mass-spectrometric detection) at Quintiles Scotland Ltd (Edinburgh,
UK) [<a href="#b19" rid="b19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_384404583">19</a>]. Briefly, rosuvastatin was extracted from
the samples by automated solid-phase extraction on 96-well plates
containing a hydrophobic-lipophilic balanced copolymer sorbent
using a Genesis RSP100 robotic sample-preparation system (Tecan,
Reading, UK). The extract was injected onto a high-performance
liquid chromatography column (a Luna column C<sub>18</sub>(2) 5 µm
(4.6 mm i.d. × 150 mm l); the mobile phase was methanol : 0.2%
formic acid in distilled water (70 : 30 v/v), and the flow rate was
1 ml min<sup>−1</sup>). Rosuvastatin was detected using a PE-Sciex
API 365 triple quadruple mass spectrometer fitted with a
turbo-ionspray source. The lower limit of quantification (LOQ) of
rosuvastatin was verified as 0.1 ng ml<sup>−1</sup>. However,
because all samples were diluted two-fold prior to assay, the
effective LOQ was 0.2 ng ml<sup>−1</sup>. The coefficient of
variation at the LOQ was ≤ 30%, and at 1 ng ml<sup>−1</sup> was ≤
20%. Correlation coefficients for rosuvastatin calibration curves
were 0.996-0.999. Mean imprecision values and inaccuracy levels for
quality control samples were &lt; 9% and &lt; 6% (at all
concentrations), respectively.</p>
</div>
<div id="__sec10" class="sec">
<h3>Determination of HMG-CoA reductase inhibitor activity</h3>
<p id="__p18" class="p p-first">Two meaningful measures of
circulating HMG-CoA reductase inhibitor activity are possible:
active inhibitors (the sum of parent compound and active
metabolites) and total inhibitors (the sum of parent compound,
active metabolites, and inactive lactones). An interacting drug may
affect the absolute concentrations of circulating active and/or
total inhibitors, and possibly change the contribution of the
parent compound to active and/or total inhibition.</p>
<p id="__p19" class="p p-last">The blood samples taken for
rosuvastatin assay were also used to obtain plasma for active and
total inhibitor assays. Samples were analysed using a validated
method (radio-enzyme inhibition assay) at Medical Research
Laboratories (Highland Heights, KT, USA). Briefly, drug-related
components were isolated from plasma by using acetonitrile :
acetone (95 : 5) to precipitate plasma proteins. The supernatant
was assayed following hydrolysis (using potassium hydroxide to
convert inactive lactones to active acids) for total inhibitors,
and unhydrolysed for active inhibitors. The supernatant was
evaporated to dryness under nitrogen, reconstituted with distilled
water (50 µl), and incubated with buffer solution containing
<sup>14</sup>C-HMG-CoA cofactors, and HMG-CoA reductase from a
human recombinant source. The <sup>14</sup>C-mevalonate product of
the enzyme reaction was separated from the substrate, after
lactonization to <sup>14</sup>C-mevalonolactone by hydrochloric
acid, on a small ion-exchange column. The effluent from the column
(which contained the <sup>14</sup>C-mevalonolactone) was collected
into scintillation vials and counted. The results were used to
construct a standard curve. Concentrations are reported as ng
equivalents of rosuvastatin ml<sup>−1</sup>. The lower LOQ was
verified as 0.36 ng ml<sup>−1</sup> and the coefficient of
variation at the LOQ was ≤ 15%. Mean imprecision values and
inaccuracy levels for quality control samples were &lt; 11% and ≤
16% (at all concentrations), respectively.</p>
</div>
<div id="__sec11" class="sec">
<h3>Determination of ketoconazole plasma concentrations</h3>
<p id="__p20" class="p p-first">Blood samples (10 ml) were taken
before and 2 h after administration of the first dose of
ketoconazole or placebo on days 4, 5, 6 and 7 of each dosing
period. Blood samples were collected into tubes containing EDTA
anticoagulant and centrifuged. Plasma was then harvested from the
samples and stored at −20°C until assay.</p>
<p id="__p21" class="p p-last">Plasma samples were analysed using a
validated method, using high-performance liquid chromatography with
fluorescence detection at Phoenix International Life Sciences Inc.
(Montreal, Quebec, Canada). The lower LOQ was verified as 20 ng
ml<sup>−1</sup>. Mean accuracy values for quality control samples
were 96.5–104.8%, and the imprecision (coefficient of variation)
was 1.5–2.5%.</p>
</div>
<div id="__sec12" class="sec">
<h3>Pharmacokinetic parameters</h3>
<p id="__p22" class="p p-first">The primary parameters of this
trial were area under the plasma concentration-time curve from time
zero to infinity (AUC) and maximum observed plasma drug
concentration (<em>C</em><sub>max</sub>) of rosuvastatin after
dosing with ketoconazole compared with placebo. If less than 12
volunteers had AUC data available from both dosing periods, the
area under the plasma concentration-time curve from time zero to
the time of the last quantifiable concentration [AUC(0,<em>t</em>)]
was substituted as a primary parameter for all volunteers.
Secondary parameters included time to <em>C</em><sub>max</sub>
(<em>t</em><sub>max</sub>), and terminal elimination half-life
(<em>t</em><sub>½</sub>) of rosuvastatin, area under the plasma
concentration-time curve and <em>C</em><sub>max</sub> of active and
total HMG-CoA reductase inhibitors, and plasma drug concentration
of ketoconazole before and 2 h after administration of the first
dose on days 4–7.</p>
<p id="__p23" class="p p-last">AUC was determined using the linear
trapezoidal rule from time zero to the time of the last
quantifiable concentration followed by extrapolation to infinity
using the terminal elimination rate constant (λ<sub>z</sub>,
calculated by log-linear regression of the terminal portion of the
plasma concentration-time curves). AUC(0,<em>t</em>) was determined
using the linear trapezoidal rule. <em>C</em><sub>max</sub> and
<em>t</em><sub>max</sub> were determined by visual inspection of
the plasma concentration-time curves, <em>t</em><sub>½</sub> was
calculated from the expression 0.693/λ<sub>z</sub>.</p>
</div>
<div id="__sec13" class="sec">
<h3>Statistical methods</h3>
<p id="__p24" class="p p-first">The trial had more than 90% power
to ensure that the 90% confidence interval (CI) for the treatment
ratio (rosuvastatin + ketoconazole/rosuvastatin + placebo) of the
geometric least square means (gls<sub>means</sub>) for rosuvastatin
AUC [or AUC(0,<em>t</em>)] was contained within the interval of
0.7–1.43 (which represented an increase of 43% or a decrease of
30%). If the 90% CI fell within this prespecified interval, the
absence of an interaction was assumed [<a href="#b20" rid="b20"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180320">20</a>].</p>
<p id="__p25" class="p p-last">As rosuvastatin AUC [or
AUC(0,<em>t</em>)] and <em>C</em><sub>max</sub> were the primary
parameters upon which sizing of the trial was based, only these
were analysed statistically. The parameters were log-transformed
and analysed using an analysis of variance model (<span class=
"small-caps">anova</span>), which accounted for the effects of
volunteer, period, and treatment. The results are presented as
gls<sub>means</sub>, treatment ratios, and the 90% CIs on the
treatment ratios.</p>
</div>
<div id="__sec14" class="sec sec-last">
<h3>Safety assessments</h3>
<p id="__p26" class="p p-first-last">The following safety
assessments were performed: adverse event reports, clinical
laboratory data (clinical chemistry, haematology, and urinalysis),
vital signs, ECGs, and medical examinations.</p>
</div>
</div>
<div id="__sec15" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec15title">Results</h2>
<p id="__p27" class="p p-first">The geometric mean
(g<sub>mean</sub>) plasma concentrations of rosuvastatin over time
were similar when rosuvastatin was coadministered with ketoconazole
and placebo (<a href="/pmc/articles/PMC1884190/figure/fig01/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1</span></a>). As AUC data from both dosing periods were available
for less than 12 volunteers, AUC(0,<em>t</em>) was substituted as a
primary parameter and subjected to statistical analysis.
AUC(0,<em>t</em>) represented a high proportion (on average 96.8%)
of AUC (where it was possible to determine a reliable value), and
thus was considered to be a suitable replacement for AUC in the
assessment of exposure. Following coadministration with
ketoconazole, rosuvastatin gls<sub>mean</sub> AUC(0,<em>t</em>) and
<em>C</em><sub>max</sub> were unchanged compared with placebo
(<a href="/pmc/articles/PMC1884190/table/tbl1/" target="true"
class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). The 90% CIs
for the treatment ratios fell within the prespecified interval of
0.7–1.43, so it was concluded that ketoconazole had no effect on
the pharmacokinetics of rosuvastatin.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884190/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC1884190/bin/bcp0055-0094-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC1884190/bin/bcp0055-0094-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884190/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Geometric mean plasma concentrations of rosuvastatin
over time when coadministered with ketoconazole or placebo. ○,
Rosuvastatin + ketoconazole; ▪, rosuvastatin +
placebo.</span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC1884190/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC1884190/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC1884190/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884190/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Summary pharmacokinetic parameters of rosuvastatin, and
results of the statistical analysis of the plasma AUC(0,<em>t</em>)
and <em>C</em><sub>max</sub> of rosuvastatin, when coadministered
with ketoconazole and placebo</span></div>
</div>
</div>
<p id="__p28">Comparison of areas under the plasma
concentration-time curves measured to a common point for
rosuvastatin and active and total HMG-CoA reductase inhibitors
indicated that, within the accuracy and precision s of the methods
used, rosuvastatin accounted for essentially all of the circulating
active inhibitors and most (&gt; 85%) of the total inhibitors
(<a href="/pmc/articles/PMC1884190/figure/fig02/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
The active inhibitors accounted for the majority (≥ 75%) of the
total circulating inhibitors (<a href=
"/pmc/articles/PMC1884190/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
Ketoconazole did not affect the proportion of circulating active or
total HMG-CoA reductase inhibitors accounted for by circulating
rosuvastatin.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884190/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC1884190/bin/bcp0055-0094-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC1884190/bin/bcp0055-0094-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884190/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>Geometric mean plasma concentrations of active and total
HMG-CoA reductase inhibitors and rosuvastatin over time when
rosuvastatin was coadministered with ketoconazole. A similar
pattern was seen when rosuvastatin was coadministered with placebo.
○,</span> <strong>...</strong></div>
</div>
</div>
<p id="__p29">The g<sub>mean</sub> plasma concentrations of
ketoconazole before administration of the first dose on days 4–7
(data not shown) indicated that steady state was achieved before
dosing with rosuvastatin and was maintained during sampling. The
g<sub>mean</sub> plasma concentrations of ketoconazole 2 h after
administration of the first dose on days 4–7 (4522, 6060, 6060,
5352 ng ml<sup>−1</sup>, respectively) suggested that
concentrations fell within the range anticipated for a 200-mg dose
of ketoconazole.</p>
<p id="__p30" class="p p-last">Rosuvastatin and ketoconazole were
well tolerated when coadministered. There were no serious adverse
events and no clinically relevant changes in clinical laboratory
parameters, vital signs, ECGs, or medical examinations during this
trial.</p>
</div>
<div id="__sec16" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec16title">Discussion</h2>
<p id="__p31" class="p p-first">Coadministration of rosuvastatin
and the potent CYP3A4 inhibitor ketoconazole did not produce any
change in pharmacokinetics of the former. Furthermore, the results
suggest that ketoconazole had no effect on the systemic clearance
of rosuvastatin, as individual plasma concentration profiles,
including the terminal elimination phase (where defined), were
similar between dosing periods.</p>
<p id="__p32">In contrast to rosuvastatin, atorvastatin [<a href=
"#b5" rid="b5" class=" bibr popnode">5</a>], simvastatin [<a href=
"#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180326">6</a>], and lovastatin [<a href="#b7" rid="b7"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180329">7</a>] are cleared primarily by metabolism
involving CYP3A4 and are known to interact with CYP3A4 inhibitors
[<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180311">8</a>–<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180325">14</a>]. The increased circulating concentrations
of these HMG-CoA reductase inhibitors reported following
coadministration with CYP3A4 inhibitors may enhance the risk for
serious adverse events such as skeletal muscle toxicity [<a href=
"#b12" rid="b12" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180317">12</a>, <a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180323">14</a>].</p>
<p id="__p33">Circulating active and total HMG-CoA reductase
inhibitor concentrations were measured in this trial. The finding
that rosuvastatin accounted for essentially all of the circulating
active inhibitors suggests the presence of only a small amount of
circulating metabolite(s). The finding that the active inhibitors,
and therefore rosuvastatin, constituted the majority of the total
inhibitors indicates the presence of only a small proportion of
circulating drug-related species with the potential to generate
pharmacologically active species (i.e. lactones). These results
provide good support for previous data indicating limited
metabolism of rosuvastatin [<a href="#b3" rid="b3" class=
" bibr popnode">3</a>, <a href="#b4" rid="b4" class=
" bibr popnode">4</a>].</p>
<p id="__p34">Other HMG-CoA reductase inhibitors have circulating
metabolites that contribute significantly to inhibitory activity.
Following coadministration with a CYP3A4 inhibitor, the absolute
concentrations of HMG-CoA reductase inhibitors and the relative
proportions of the parent compound and its metabolites may be
affected. For example, in the case of atorvastatin, following
coadministration with itraconazole, the mean AUC(0,72) of the
active and total inhibitors was increased 1.6- and 1.7-fold,
respectively; the mean AUC(0,72) of atorvastatin acid and lactone
was increased 3.2- and 4.1-fold, respectively; and the mean
AUC(0,72) of the principal metabolite 2-hydroxyatorvastatin acid
and its lactone was decreased by 57% and 38%, respectively
[<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180313">10</a>].</p>
<p id="__p35">There is increasing awareness that drug interactions
can also occur as a result of competition for, or induction or
inhibition of, transport proteins. Ketoconazole is known to have
inhibitory effects on the transport protein P-gp [<a href="#b16"
rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180322">16</a>]. Active- or facilitated-transport
processes may have a role in the absorption and disposition of
rosuvastatin [<a href="#b17" rid="b17" class=
" bibr popnode">17</a>, <a href="#b18" rid="b18" class=
" bibr popnode">18</a>]. The identity of the rosuvastatin
transporters that interact with rosuvastatin has not been clearly
defined, but if it were a P-gp substrate, an increase in
rosuvastatin exposure would be expected following coadministration
with ketoconazole. The potency of ketoconazole to inhibit P-gp has
been assessed in cell-based assays and <em>in vivo</em> animal
experiments [<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180312">16</a>]. Based on these data, it is likely that
the concentrations of ketoconazole achieved in the present study
would have caused a degree of P-gp inhibition [<a href="#b16" rid=
"b16" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130180332">16</a>]. Therefore, our results suggest that
rosuvastatin is not a ligand for P-gp. This finding is in agreement
with the results of a study that showed no effect of rosuvastatin
on the pharmacokinetics of the P-gp substrate digoxin [<a href=
"#b21" rid="b21" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_341082010">21</a>].</p>
<p id="__p36" class="p p-last">In conclusion, ketoconazole did not
affect the pharmacokinetics of rosuvastatin in healthy subjects.
Therefore, coadministration of ketoconazole and rosuvastatin is
unlikely to increase the risk of toxicity at therapeutic doses of
rosuvastatin. The data suggest that neither cytochrome P450 3A4 nor
P-gp-mediated transport contributes to the elimination of
rosuvastatin.</p>
</div>
<div id="__ackid268780" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid268780title">
Acknowledgments</h2>
<div class="sec">
<p id="__p37">The authors thank Quintiles Scotland Ltd (Edinburgh,
UK) for performing the rosuvastatin assays, Medical Research
Laboratories (Highland Heights, Kentucky, USA) for performing the
HMG-CoA reductase inhibitor assays, Phoenix International Life
Sciences Inc. (Montreal, Quebec, Canada) for performing the
ketoconazole assays, Olise M. Nwose MB BS for his support of this
trial, and Elizabeth Eaton PhD for manuscript preparation.</p>
</div>
</div>
<div id="__ref-listid268790" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid268790title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"citation">Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect
of rosuvastatin on low-density lipoprotein cholesterol in patients
with hypercholesterolemia. <span><span class="ref-journal">Am J
Cardiol.</span> 2001;<span class=
"ref-vol">88</span>:504–508.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11524058" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"citation">Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No
effect of age or gender on the pharmacokinetics of rosuvastatin—a
new HMG-CoA reductase inhibitor. <span><span class="ref-journal">J
Clin Pharmacol.</span> 2002</span> in press. <span class=
"nowrap ref pubmed">[<a href="/pubmed/12362926" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"citation">Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition
of new HMG-CoA reductase inhibitor ZD4522 following dosing in
healthy subjects. <span><span class="ref-journal">J Clin
Pharmacol.</span> 2000;<span class="ref-vol">40</span>:1056.</span>
[Abstr. 48]</span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"citation">McCormick AD, McKillop D, Butters CJ, et al. ZD4522—an
HMG-CoA reductase inhibitor free of metabolically mediated drug
interactions: metabolic studies in human <em>in vitro</em> systems.
<span><span class="ref-journal">J Clin Pharmacol.</span>
2000;<span class="ref-vol">40</span>:1055.</span> [Abstr.
46]</span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"citation">Michniewicz BM, Black AE, Sinz MW, Woolf TF. <em>In
vitro</em> and <em>in vivo</em> metabolism of atorvastatin (CI-981)
l. <span><span class="ref-journal">ISSX Proc.</span>
1994;<span class="ref-vol">6</span>:93.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"citation">Prueksaritanont T, Gorham LM, Ma B, et al. <em>In
vitro</em> metabolism of simvastatin in humans (SBT) identification
of metabolizing enzymes and effect of the drug on hepatic P450s.
<span><span class="ref-journal">Drug Metab Dispos.</span>
1997;<span class="ref-vol">25</span>:1191–1199.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9321523" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"citation">Jacobsen W, Kirchner G, Hallensleben K, et al.
Comparison of cytochrome P-450-dependent metabolism and drug
interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase
inhibitors lovastatin and pravastatin in the liver.
<span><span class="ref-journal">Drug Metab Dispos.</span>
1999;<span class="ref-vol">27</span>:173–179.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9929499" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"citation">Siedlik PH, Olson SC, Yang B-B, Stern RH. Erythromycin
coadministration increases plasma atorvastatin concentrations.
<span><span class="ref-journal">J Clin Pharmacol.</span>
1999;<span class="ref-vol">39</span>:501–504.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10234598" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"citation">Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri
J, Sundaresen P. Itraconazole alters the pharmacokinetics of
atorvastatin to a greater extent than either cerivastatin or
pravastatin. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2000;<span class="ref-vol">68</span>:391–400.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/11061579" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"citation">Kantola T, Kivistö KT, Neuvonen PJ. Effect of
itraconazole on the pharmacokinetics of atorvastatin.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
1998;<span class="ref-vol">64</span>:58–65.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9695720" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"citation">Kantola T, Kivistõ KT, Neuvonen PJ. Erythromycin and
verapamil considerably increase serum simvastatin and simvastatin
acid concentrations. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 1998;<span class="ref-vol">64</span>:177–182.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9728898" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"citation">Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not
pravastatin is very susceptible to interaction with the CYP3A4
inhibitor itraconazole. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 1998;<span class=
"ref-vol">63</span>:332–341.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9542477" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"citation">Kivistö KT, Kantola T, Neuvonen PJ. Different effects of
itraconazole on the pharmacokinetics of fluvastatin and lovastatin.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
1998;<span class="ref-vol">46</span>:49–53.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1873980/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9690949" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"citation">Neuvonen PJ, Jalava KM. Itraconazole drastically
increases plasma concentrations of lovastatin and lovastatin acid.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
1996;<span class="ref-vol">60</span>:54–61.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8689812" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"citation">Albengres E, Le Louët H, Tillement J-P. Systemic
antifungal agents. Drug interactions of clinical significance.
<span><span class="ref-journal">Drug Saf.</span> 1998;<span class=
"ref-vol">18</span>:83–97.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9512916" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"citation">Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects
of the antifungal agents on oxidative drug metabolism.
<span><span class="ref-journal">Clin Pharmacokinet.</span>
2000;<span class="ref-vol">38</span>:111–180.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10709776" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"citation">Nezasa K, Takeuchi M, Yukawa T, et al. Tissue specific
distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitor, to the liver in rats l. <span><span class=
"ref-journal">Xenobiotic Metab Dispos.</span> 1998;<span class=
"ref-vol">13</span>(Suppl):S226.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"citation">Brown CDA, Windass A, Bleasby K, Lauffart B.
Rosuvastatin is a high affinity substrate of hepatic organic anion
transporter OATP-C l. <span><span class="ref-journal">Atheroscler
Suppl.</span> 2001;<span class="ref-vol">2</span>:90.</span>
(P174)</span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"citation">Hull CK, Penman AD, Smith CK, Martin PD. Quantification
of rosuvastatin in human plasma by automated solid-phase extraction
using tandem mass-spectrometric detection. <span><span class=
"ref-journal">J Chromatogr B Biomed Appl.</span> 2002</span> in
press. <span class="nowrap ref pubmed">[<a href="/pubmed/12007766"
target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"citation">Tucker GT, Houston JB, Huang S-M. Optimizing drug
development: strategies to assess drug metabolism/transporter
interaction potential—toward a consensus. <span><span class=
"ref-journal">Br J Clin Pharmacol.</span> 2001;<span class=
"ref-vol">52</span>:107–117.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC2014497/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/11453898" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"citation">Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No
effect of rosuvastatin on the pharmacokinetics of digoxin in
healthy volunteers l. <span><span class=
"ref-journal">Pharmacotherapy.</span> 2001;<span class=
"ref-vol">21</span>:1255.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12463730" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884190&amp;issue-id=144659&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC1884190/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC1884190/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC1884190/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC1884190/pdf/bcp0055-0094.pdf">PDF
(98K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC1884190" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F&amp;text=Lack%20of%20effect%20of%20ketoconazole%20on%20the%20pharmacokinetics%20of%20rosuvastatin%20in%20healthy%20subjects">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884190%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="12534645" data-aiid="1884190"
data-aid="1884190" data-iid="144659" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC1884190" data-md5=
"097d03ef45265370fe730c10eb4235a0"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-16T15:42:38-04:00&amp;Host=ptpmc202">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1884190/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FC2AE5763012E1_0162SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
